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Abstract
Background Non-adherence to medications is prevalent
across all medical conditions that include ambulatory
pharmacotherapy and is thus a major barrier to achieving
the benefits of otherwise effective medicines.
Objective The objective of this systematic review was to
identify and to compare the efficacy of strategies and
components thereof that improve implementation of the
prescribed drug dosing regimen and maintain long-term
persistence, based on quantitative evaluation of effect sizes
across the aggregated trials.
Data sources MEDLINE, EMBASE, CINAHL, the
Cochrane Library, and PsycINFO were systematically
searched for randomized controlled trials that tested the
efficacy of adherence-enhancing strategies with self-
administered medications. The searches were limited to
papers in the English language and were included from
database inception to 31 December 2011.
Study selection Our review included randomized con-
trolled trials in which adherence was assessed by elec-
tronically compiled drug dosing histories. Five thousand
four hundred studies were screened. Eligibility assessment
was performed independently by two reviewers. A struc-
tured data collection sheet was developed to extract data
from each study.
Study appraisal and synthesis methods The adherence-
enhancing components were classified in eight categories.
Quality of the papers was assessed using the criteria of the
Cochrane Handbook for Systematic Reviews of Interven-
tions guidelines to assess potential bias. A combined
adherence outcome was derived from the different adher-
ence variables available in the studies by extracting from
each paper the available adherence summary variables in a
pre-defined order (correct dosing, taking adherence, timing
adherence, percentage of adherent patients). To study the
Electronic supplementary material The online version of this
article (doi:10.1007/s40265-013-0041-3) contains supplementary
material, which is available to authorized users.
J. Demonceau  P. Kristanto  J. Urquhart  B. Vrijens
AARDEX Group Ltd., a MWV Healthcare Company, Sion,
Switzerland
T. Ruppar  S. De Geest  F. Dobbels
Health Services and Nursing Research, Department of Public
Health, University of Leuven, Leuven, Belgium
T. Ruppar
Sinclair School of Nursing, University of Missouri,
Columbia, USA
D. A. Hughes  E. Fargher
Centre for Health Economics and Medicines Evaluation,
Bangor University, Bangor, Wales
P. Kardas  P. Lewek
Medical University of Lodz, Lodz, Poland
S. De Geest
Institute of Nursing Science, Faculty of Medicine, University of
Basel, Basel, Switzerland
J. Urquhart
Department of Bioengineering and Therapeutic Sciences,
UCSF, San Francisco, USA
B. Vrijens
Department of Biostatistics and Medical Informatics,
University of Lie`ge, Lie`ge, Belgium
B. Vrijens (&)
AARDEX Group Ltd, Rue des Cyclistes Frontie`re,




association between the adherence-enhancing components
and their effect on adherence, a linear meta-regression
model, based on mean adherence point estimates, and a
meta-analysis were conducted.
Results Seventy-nine clinical trials published between
1995 and December 2011 were included in the review.
Patients randomized to an intervention group had an
average combined adherence outcome of 74.3 %, which
was 14.1 % higher than in patients randomized to the
control group (60.2 %). The linear meta-regression analy-
sis with stepwise variable selection estimated an 8.8 %
increase in adherence when the intervention included
feedback to the patients of their recent dosing history (EM-
feedback) (p \ 0.01) and a 5.0 % increase in adherence
when the intervention included a cognitive-educational
component (p = 0.02). In addition, the effect of interven-
tions on adherence decreased by 1.1 % each month. Sen-
sitivity analysis by selecting only high-quality papers
confirmed the robustness of the model. The random effects
model in the meta-analysis, conducted on 48 studies,
confirmed the above findings and showed that the
improvement in adherence was 19.8 % (95 % CI
10.7–28.9 %) among patients receiving EM-feedback,
almost double the improvement in adherence for studies
that did not include this type of feedback [10.3 % (95 % CI
7.5–13.1 %)] (p \ 0.01). The improvement in adherence
was 16.1 % (95 % CI 10.7–21.6 %) in studies that tested
cognitive-educational components versus 10.1 % (95 % CI
6.6–13.6 %) in studies that did not include this type of
intervention (p = 0.04). Among 57 studies measuring
clinical outcomes, only 8 reported a significant improve-
ment in clinical outcome.
Limitations Despite a common measurement, the meta-
analysis was limited by the heterogeneity of the pooled
data and the different measures of medication adherence.
The funnel plot showed a possible publication bias in
studies with high variability of the intervention effect.
Conclusions Notwithstanding the statistical heterogeneity
among the studies identified, and potential publication bias,
the evidence from our meta-analysis suggests that EM-
feedback and cognitive-educational interventions are
potentially effective approaches to enhance patient adher-
ence to medications. The limitations of this research
highlight the urgent need to define guidelines and study
characteristics for research protocols that can guide
researchers in designing studies to assess the effects of
adherence-enhancing interventions.
1 Introduction
Adequate adherence to medications of proven efficacy and
acceptable safety is essential for realizing their health
benefits. Yet, suboptimal adherence to prescribed medica-
tion regimens is prevalent across all clinical conditions and
populations [1].
In the setting of chronic conditions, non-adherence to
medications generally worsens outcomes of treatments,
leading to increased risk of adverse medical events, more
consultations with physicians, higher rates of hospitaliza-
tion, and increased health care costs [1–5]. Non-adherence
has recently been estimated to cost the US health care
system $310 billion annually [6] with the associated eco-
nomic burden being specific to disease severity, co-mor-
bidity, and the respective severities of co-morbidities [7].
Many reasons exist for non-adherence to medicines, and
knowledge of these could help clinicians to target patients
in need of intervention, design these interventions, and help
researchers to plan studies of adherence.
Several reviews [8–11] of interventions for enhancing
adherence to medications have consistently highlighted
methodological weaknesses in the study designs and
methods used, often precluding quantification and permit-
ting only qualitative assessments. In particular, there are
major between-study differences in methods used to assess
adherence, differing not only in reliability but also in the
degree of temporal resolution of their measurements. These
methodological differences have thus hampered the iden-
tification of interventions that can effectively enhance
adherence to medications.
Among the different measurement methods available,
electronic medication-event monitoring, which consists of
automatic compilation of the time history of each patient’s
entry into the drug package, has been considered to provide
the most reliable data on adherence in complex clinical
situations and in the setting of clinical trials and adherence
research [1]. Moreover, it has been reported that electronic
medication-event monitoring is the most accurate method
for identifying non-adherence [12–14]. Several studies
confirm that package opening times are a robust indicator
of the times at which patients take the prescribed doses
[15–17].
Electronically-compiled dosing histories may also be
used as part of the adherence-enhancing intervention, by
allowing the health professional to provide feedback to the
patient on his/her dosing history. This approach has been
referred to as ‘‘Measurement-Guided Medication Man-
agement (MGMM)’’ [4].
In the present study, we have systematically searched
the literature to identify randomized controlled trials
(RCTs) containing empirical data on the efficacy of inter-
ventions to enhance adherence to prescribed medications,
as assessed by electronic medication-event monitoring
methods.
This research was performed within the Ascertaining
Barriers to Compliance (ABC) Project, which is an
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international collaboration of European research groups in
the field of adherence to medications funded by the Euro-
pean Commission, Seventh Framework Programme [18].
2 Methods
The reporting of this systematic review follows the
PRISMA guidelines [19].
2.1 Eligibility Criteria
We included RCTs, including cross-over and cluster-ran-
domized trials, containing empirical data on interventions
expected to enhance adherence to prescribed medications
in adults and children, where adherence was assessed by
electronic medication-event monitoring methods.
Papers were excluded for the following reasons:
(1) Studies that did not focus on adherence to medica-
tions; (2) studies in which adherence was not measured
electronically in all patients enrolled in the clinical trial; (3)
studies that were not RCTs; (4) studies that focused on
interventions to improve disease or symptom management;
(5) studies that did not include an adherence intervention;
(6) studies in which no quantifiable adherence data were
reported; (7) studies that did not report a formal compari-
son of adherence data between intervention and control
conditions; (7) double citations. No paper was excluded on
the grounds of quality.
2.2 Information Sources
MEDLINE, EMBASE, CINAHL, the Cochrane Library,
and PsycINFO were searched for all papers testing adher-
ence-enhancing interventions. The searches were limited to
papers in the English language and were included from
database inception to 31 December 2011. Detailed search
strategies specific to the different databases are provided in
Appendix 1 in the Electronic Supplementary Material
(ESM).
2.3 Study Selection
Eligibility assessment of title and abstract was performed
independently in an unblinded standardized manner by two
reviewers (JD, TR). If one reviewer coded a study as
potentially eligible, the paper was included for full-text
review. The full texts of potentially eligible papers were
retrieved and reviewed in the second stage of the screening
process. Disagreements were resolved by discussion, and a
final decision was reached between the two reviewers.
2.4 Data Collection Process
A structured data collection sheet was developed to extract
data from each study. All data were extracted from the
papers; no additional information was sought from authors.
The following paragraphs describe which data were
extracted.
2.5 Data Items
2.5.1 Types of Participants
Studies including ambulatory patients who were prescribed
medications for any medical disease were considered for
this review.
Demographic data, such as sample size of each study
group, population age, percentage of female subjects in
each group, and ethnicity of the patients, were extracted
from each paper.
2.5.2 Categorization of Interventions
Any intervention or combination of interventions intended
to affect adherence to self-administered prescribed medi-
cations in short-term and in long-term therapy.
The adherence-enhancing components were classified in
eight categories, based on a taxonomy developed from
other sources [10, 20–22].
1. Interventions based on a treatment simplification (TRT
simpl) consist of changes in the dosage schedule (e.g.,
once daily vs. twice daily) or a change in formulation
(e.g., change from tablets to liquid formulation);
2. Cognitive-educational interventions (Cogn-Educ)
present information individually or in a group setting,
delivering it verbally, in written form, and/or audiovi-
sually. These interventions are designed to educate and
motivate patients based on the concept that patients
who understand their condition and its treatment will
be more informed, more empowered and more likely
to adhere [10, 20, 21];
3. Behavioral-counseling interventions (Behav-Counsel)
shape and/or reinforce behavior, and empower patients
to participate in their own care, while positively
changing their skill levels or normal routines (e.g.,
skill building by a health care professional, pillboxes,
calendars, steps intended to remind the patient to take
the medication or tailor the regimen to the patient’s
daily routine) and problem solving [10, 20, 21];
4. Social-psycho-affective interventions (Soc-Psych)
focus on patients’ feelings and emotions or social
relationships and social support (e.g., family counsel-
ing, group meetings with peers or another groups,
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stress management) [10, 20], as long as the interven-
tions are based on the assumptions that cognitions can
be monitored and altered, and in turn may facilitate
behavior change [22];
5. Interventions based on electronically monitored adher-
ence feedback (EM-feedback) are designed to provide
feedback on patients’ dosing histories compiled from
electronic medication-event methods;
6. Interventions based on technical reminder systems
(Tech rem) are designed to provide technical devices to
remind the patients when it is time to take their
medications (e.g., mobile phone text message, pager,
electronic monitor with beeper);
7. Interventions using technical equipment for monitoring
the disease being managed (Tech equip) are designed
to use various technologies to provide patients with
feedback on a clinical outcome (e.g., glucose meter,
BP home measurement, feedback on laboratory
results);
8. Rewards: any kind of rewards for adhering to medi-
cation (e.g., cash reinforcement, toys for children).
2.5.3 Types of Studies
Randomized controlled trials, including cross-over and
cluster-randomized trials, which tested the effectiveness
of adherence-enhancing interventions in an intervention
group versus a control group receiving no intervention,
e.g., usual care. Adherence had to be assessed through
electronically compiled dosing histories in all patients.
Studies with small sample sizes were included. Although
they often lack statistical power, small studies sometimes
contribute novel interventions or target difficult-to-recruit
populations.
cStudy design, number of monitored medications, types
of electronic medication-event monitoring, and information
on the condition being managed (medical condition, regi-
men, type of administration) were extracted from each
study.
2.5.4 Types of Outcome Measures
Studies in which medication adherence was reported as the
primary or secondary outcome assessed with any kind of
electronic medication-event monitoring system. We did not
assess the quality of the selected studies in regard to
whether or not the study was appropriately powered to
detect differences in adherence. Clinical outcomes were
extracted if reported.
2.5.4.1 Adherence Definitions A range of variables was
extracted, according to reporting in the primary studies.
These were labeled as follows over the relevant reporting
period:
• Correct dosing was defined as the percentage of
treatment days with the correct number of doses taken;
• Taking adherence was defined as the percentage of
prescribed doses taken;
• Timing adherence was defined as the percentage of
doses taken within a pre-defined time window;
• Percentage of adherent patients was defined as the
percentage of patients with adherence measures greater
than a pre-defined value.
Data on mean adherence outcomes were extracted for
each reported adherence variable, with a 95 % confidence
interval (CI) or standard deviation (SD) for all the study
groups. Each study may however report the result of the
adherence intervention using one summary variable and
not the others. Therefore, to take into account all studies
available for the analysis, a combined adherence outcome
was defined by selecting the available adherence summary
variable of each paper in the following order: correct
dosing, taking adherence, timing adherence, and percent-
age of adherent patients. To study the association between
the adherence-enhancing components and their effect on
adherence, the analyzed outcome variable was the differ-
ence in reported adherence percentages between the
intervention group and the control group. If adherence
outcomes were reported at several time points, the outcome
reported at the end of the intervention period was coded for
each study.
2.5.4.2 Health Outcomes Data on clinical outcomes were
extracted and reported as a significant or non-significant
difference between study groups. We did not assess the
quality of the selected studies with regard to whether or not
the study was appropriately powered to detect differences
in clinical outcomes.
2.6 Risk of Bias in Individual Studies
A quality assessment of the articles included in this review
was processed by two independent reviewers (PK, JD) after
the data collection process. The evaluation was based on
the assessment of potential bias as reported in the Coch-
rane Handbook for Systematic Reviews of Interventions
(http://www.cochrane-handbook.org/) [23]. The studies
were assessed based on their risk of: (1) selection bias
(biased allocation to interventions) due to inadequate
generation of a randomised sequence, (2) attrition bias due
to the amount, nature, or handling of incomplete outcome
data, (3) reporting bias due to selective outcome reporting,
and (4) risk of contamination of the intervention to the
control group. For each type of possible bias, the articles
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were given a score -1 (high risk of bias), 0 (unclear risk of
bias), or ?1 (low risk of bias). Total score for bias ranged
from -4 to ?4 with studies scored between -4 and 0
considered as being of lower quality.
2.7 Synthesis of Results
Descriptive statistics (mean, SD, median, IQR, minimum,
maximum) were used to summarize the structured data
retrieved from the reviewed papers. Box–whisker plots
were used to illustrate the data graphically.
When more than one type of intervention was tested,
data from each arm of the study were considered as sepa-
rate data points. A sensitivity analysis was performed to
check for potential bias resulting from over-representation
of studies with more than one intervention arm (see ESM).
In a first step, the mean adherence (point estimate) was
considered for univariate and multivariate linear regression
analysis. The dependent variable of those models was the
difference in the adherence outcome between the inter-
vention and control groups of each study. In the model-
building process, the effect of each available potentially
confounding factor on the combined adherence outcome
was tested using a linear meta-regression model.
The following were included as explanatory variables:
medical condition, unit of allocation at randomization
(randomization by patients or centers), average age, per-
centage of females, number of subjects in the intervention
group, study duration (in weeks), the type of adherence
outcome measure used in the analysis, the category of
adherence-enhancing intervention, and the effect of the
occupation of the person delivering the intervention (phy-
sician, nurse, pharmacists, or support partner). A stepwise
regression procedure with forward selection and a t statistic
equal to 2 were used to define the final model.
For the studies in which the SD of the adherence out-
come was reported together with its mean, we conducted a
more formal estimation of the adherence-enhancing effect,
measured by the difference between the adherence out-
come of each intervention and the control group of each
study (and aggregated 95 % confidence interval) resulting
from the different intervention types identified.
In the meta-analysis, a random effects model was used.
The random effects model was fitted using a two-step
approach [24]. First, the amount of residual/heterogeneity
(s2) was estimated by random effects model using restric-
ted maximum-likelihood method [24, 25]. Then the true
effect was estimated using weighted least squares with
weight of study i equal to wi = 1/(vi ? s
2), where vi is the
sampling variance of study i and s2 is the variability among
the true effects that is not accounted for by the model. The
analysis was executed using metafor package [26]
implemented in R statistical package version 2.13.2. Total
variability due to heterogeneity (I2) and Q test were used to
assess the statistical heterogeneity of the studies.
2.8 Risk of Bias Across Studies
A funnel plot was used to assess the presence of publica-
tion bias across studies. The funnel plot shows the indi-
vidual observed effect sizes or outcomes on the x axis
against the corresponding standard errors (i.e., the square
root of the sampling variances) on the y axis [27].
3 Results
3.1 Study Selection
Seventy-nine RCTs were included in the review. An
overview of the review process and reasons for exclusion at
the different steps are displayed in Fig. 1.
3.2 Study Characteristics
Individual study characteristics are listed in Appendix 2 in
ESM. The majority of the studies were two-arm studies
with one intervention group compared with one control
group. However, 5 [28–32] of the 79 studies were 3-arm or
4-arm studies testing the efficacy of more than one
adherence-enhancing component, each compared with the
same control group. To check for potential bias resulting
from over-representation of studies with more than one
intervention arm, a sensitivity analysis was performed. In
this analysis, studies with multiple intervention arms were
(1) excluded, (2) only a single intervention arm was kept
for analysis, or (3) each intervention arm was considered as
a separate study. The resulting difference in parameter
estimates between the three approaches was marginal
(\1 %). Therefore, in the remainder of the paper, each
intervention arm was considered as a separate study for
analysis, yielding 87 cohorts totaling 5,237 subjects.
3.2.1 Types of Participants
Mean sample size expressed as number of subjects was
61.4 [range (5; 1,113)] in the usual care group and 64.1
[range (4; 1,189)] in the intervention group.
Average age expressed in years was 47.5 [range (3.0;
73.7)] in the usual care group and 46.8 [range (3.4; 76.2)]
in the intervention group. Five studies [33–37] designed
adherence-enhancing interventions for children. Partici-
pants’ demographic characteristics are presented in
Tables 1 and 2.
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3.2.2 Categorization of Interventions
In 40 intervention groups, the efficacy of only one adherence-
enhancing component was tested against a control group,
whereas in 47 intervention groups a combination of multiple
adherence-enhancing components was tested (Fig. 2).
The average intervention period was 19.4 weeks with a
range of 0–52 weeks. In two studies [38, 39], the intervention
was delivered only on one occasion to the patients. In both of
these studies, the patient post-intervention follow-up period
ranged from 4 weeks [39] to 12 weeks [38]. The median
duration of patient follow-up was 26 weeks [range (4; 64)].
Table 1 Group of patients targeted by the interventions in the 87
intervention groups
Types of participants n %




Socioeconomically disadvantaged patients 3 3.4
Postmenopausal women 3 3.4
Depressive patients 2 2.3
Soldiers 1 1.1
Adults commonly underrepresented in research
(female, African American, Hispanics)
1 1.1
African Americans 1 1.1
Pregnant women 1 1.1
HIV patients with memory impairment 1 1.1
Methadone clinic patients 1 1.1




Mean sample size expressed as
number of subjects (min–max)
(n = 82)
61.4 (5–1,113) 64.1 (4–1,189)
Average age expressed in years
(min–max) (n = 60)
47.5 (3.0–73.7) 46.8 (3.4–76.2)
Gender expressed as % female
(n = 59)
55.3 % 55.5 %
Ethnicity expressed as %
Caucasian (n = 28)
36.0 % 39.5 %
Fig. 1 Flow diagram of study selection process. CI confidence interval, SD standard deviation
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The frequency with which the intervention was deliv-
ered to patients was not included as a variable in the meta-
analysis and was presumably optimized based on the type
of intervention. In studies in which multiple intervention
components were part of the adherence-enhancing inter-
vention, each intervention component was reported with a
different frequency. In several studies the frequencies were
not clearly described [40–42].
Sixty-six of the 79 control groups received routine care,
e.g., groups in which ‘usual care’ was provided to the patients
and no adherence-enhancing intervention was tested. In some
of these studies, the control groups were just named as
‘standard of care’ without a clear description of what was
exactly provided to the patients of these groups.
In 13 control groups, however, an enhanced standard of
care was provided to the patients. In one study [43], for
example, the control group received the same care as the
intervention group except for behavioral strategies. Control
patients used self-monitoring of symptoms and attended
the same number of visits as the intervention group.
3.2.3 Types of Studies
Within our selected RCTs, five were cluster randomized
[44–48], and three were cross-over studies [49–51]. The
publication years ranged from 1995 to 2011 with a peak in
2007 (n = 12). Out of five cluster-randomized studies,
three [44, 45, 47] took into account the within-cluster
(within-center) correlation to analyze the adherence inter-
vention effects.
The majority of the monitored medications were oral
medication (87.4 %) monitored with the medication event
monitoring system (MEMS) caps (85.1 %). Table 3
illustrates the principal treatment characteristics of the 87
intervention groups.
The number of medications monitored ranged from 1 to
4 in each patient. In most of the studies (89.0 %), medi-
cation adherence was assessed electronically for one
medication. In studies with multiple medications for a
single indication, typically the medication with the most
frequent or the most complicated dosing regimen was
monitored. In the majority of these studies, however,
adherence-enhancing interventions aimed to enhance
medication adherence with all prescribed medications. In
four studies [38, 40, 52, 53], it was not clear which and
how many medications were monitored.
Disease categories were broad (23 different diseases);
38.0 % of studies concerned HIV infection. Studies exclu-
sively reported patients with chronic diseases (hypertension
13.9 %, asthma 12.7 %, heart failure 5.1 %, etc.).
Three studies [54–56] provided an estimate of the
intervention’s costs. The first study [54] reported an
Fig. 2 Combination of adherence-enhancing components for each
intervention group (n = 87). Each column stands for one intervention
group. Intervention groups are ranked by number and types of
components tested. In each intervention group, the tested intervention
components are illustrated by red boxes. TRT simpl Interventions
based on treatment simplification, Cogn-Educ cognitive-educational
interventions, Behav-Counsel behavioral-counseling interventions,
Soc-Psych social-psycho-affective intervention, EM-feedback inter-
ventions based on electronic-monitoring adherence feedback, Tech
rem interventions based on a technical reminder use, Tech equip
interventions based on a technical equipment use, Rewards any kind
of rewards for adhering to medications
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intervention based on daily text message reminders sent to
the patients over a 4-week period (costs estimated per
patient: US$3.60, projected costs per year: US$46.80;
2009). The second study [55] reported that the price for an
alarmed vial used for 4 weeks ranged from US$16 to
US$80 (2001). The third study reported a cost of US$205
per patient [56] for a 1-year intervention delivered by a
trained pharmacist providing patient-centered instructions
and education (2007). No further conclusion on interven-
tion costs could be derived given the limited information
and the diversity of the studies.
3.2.4 Types of Outcome Measures
3.2.4.1 Adherence Definitions Twenty-five studies
reported correct dosing, 49 studies reported adherence as
taking adherence, 27 reported timing adherence, and 18
studies adherence as percentage of adherent patients.
Forty-eight studies reported mean adherence outcomes
with a 95 % CI or standard deviation and were therefore
included in the random effects model of the meta-analysis.
3.2.4.2 Health Outcomes Among the 57 studies that
reported data on clinical outcomes (72.2 %), only 8 [35,
44, 52, 57–61] reported a significant difference in clinical
outcome between the intervention and the control groups.
Ducharme et al. [35] showed that children receiving a
written action plan coupled with a prescription displayed
significantly better asthma control with 40 % more patients
reporting less than two indicators of poor control (relative
risk 1.36; 95 % CI 1.04; 1.86). Asthma control was mea-
sured with the Asthma Quiz for Kids, which is a validated
questionnaire measuring the number of indicators of poor
asthma control.
Delmas et al. [44] concluded that adherence reinforce-
ment strategies (feedback on bone turnover markers) were
associated with a lower incidence of new radiologically
determined vertebral fractures in osteoporosis patients
(odds ratio 0.4; 95 % CI 0.2–1.0).
Bogner et al. [52] reported fewer depressive symptoms
(CES-D mean score difference between groups: 9.3;
p \ 0.01), lower systolic blood pressure (systolic BP differ-
ence between groups: 14 mmHg; p \ 0.01), and lower dia-
stolic blood pressure (diastolic BP difference between
groups: 9.2 mmHg; p \ 0.01) in hypertensive patients of the
intervention group (integrating depression treatment with
hypertension management) compared to patients of the usual
care group. Patients’ treatment was monitored for 6 weeks.
Kardas et al. [57] noted that patients treated with once-
daily sulfonylurea drugs achieved significantly better gly-
caemic control than those treated with the twice-daily
medication (HbA1c level difference between groups:
0.9 %; p \ 0.0001).
De Bruin et al. [58] showed that the number of HIV
patients with an undetectable viral load increased in the
intervention group (theory- and evidence-based underpin-
nings of the determinants and behavior change techniques)
compared to the control group (p \ 0.05).
Another study conducted by the group of Bogner and
de-Vries [59] noted that participants in the integrated care





Eye drops 1 1.1
Topical 1 1.1
Dosing regimens
Once daily 13 14.9
Twice daily 13 14.9
Once daily vs. twice daily 12 13.8
Once daily vs. thrice daily 1 1.1
Once daily vs. once weekly 1 1.1
Variable (e.g., the medication with the most frequent
pill-taking schedule)
31 35.6
Not reported 16 18.4
Occupation of the person delivering the intervention
Nurse 28 32.2
Physician 14 16.1
Others (research assistant, community health worker,
social worker, mobile phone, etc.)
34 39.1
Pharmacist 7 8.0
Support partner 5 5.7
Psychologist 2 2.3
Not reported 11 12.6
Place where the intervention was provided
Hospital 52 59.8
Home 19 21.8
Hospital and home 10 11.5
Pharmacy 4 4.6
Primary care office 1 1.1




Metered dose inhaler (MDI) 2 2.3
Doser CT 3 3.4
RemindRX 1 1.1
Dosing aid 1 1.1
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intervention group (integrating depression treatment into
care for type 2 diabetes mellitus) had lower levels of gly-
cosylated hemoglobin (p \ 0.05) and fewer depressive
symptoms (p \ 0.04) compared to participants in the usual
care group at 12 weeks of diabetes treatment.
Rudd et al. [60] found that hypertensive patients ran-
domized to the intervention group (home-based, physician-
directed, nurse-guided drug therapy) achieved greater
reductions in office blood pressure values at 6 months than
those receiving usual care (systolic BP difference between
groups: 8.5 mmHg; p \ 0.01; diastolic BP difference
between groups: 1.4 mmHg; p \ 0.05).
Another study of Kardas [61] reported that the mean
weekly number of chest pain episodes in angina pectoris
patients was greater in patients with once-daily oral nitrates
compared to patients randomized to the twice daily regi-
men (0.94 ± 4.32 and 0.30 ± 1.20 episodes per week for
the once and twice daily regimens, respectively;
p \ 0.0001).
3.3 Synthesis of the Results
Adherence data collected from the 87 intervention studies
resulted in drug dosing history data compiled among
10,551 ambulatory patients. Patients randomized to an
intervention group had an average combined adherence
outcome of 74.3 %, which was 14.1 % higher than in
patients randomized to the control group (60.2 %). The
median difference in the combined adherence outcome was
12.6 % (range -7.0, 59.0 %; IQR 16 %).
The median difference in adherence measures between
the control and intervention group at the end of the inter-
vention period in studies that reported adherence as correct
dosing (n = 25) was 14.0 % (range 0.0, 32.0 %; IQR
12.9 %); in studies that reported taking adherence
(n = 49), the median difference was 8.3 % (range -7.0,
49.0 %; IQR 12.7 %); in studies that reported timing
adherence (n = 27), the median difference was 14.9 %
(range 2.0, 33.6 %; IQR 11.5 %); in studies that reported
the percentage of adherent patients (n = 18), the median
difference was 20.9 % (range 1.8, 59.0 %; IQR 26.4 %).
3.3.1 Potential Confounding Factors and Intervention
Components that Affect Adherence Measures
Univariate linear regression models were used to explore
the association between each potential confounding factor
and the difference in adherence measures between the
control and intervention group. The models showed that
study duration was the only factor that significantly
affected adherence measures (p \ 0.01). The longer the
patient follow-up is, the smaller the difference in the
adherence outcome between the study groups at the end of
the study (Fig. 3). For each additional month of follow-up,
the effect on adherence decreased by 1.0 %.
The number of subjects enrolled in the intervention
group, subject gender, and average patients’ age in the
intervention group did not significantly affect this differ-
ence. For each increase in the number of intervention
elements, the adherence outcome increased by 2.3 %
(p = 0.05). The results of the univariate linear regression
model are summarized in Table 4. The unit allocation of
randomization, by either patients (effect 14.1 %) or centers
(effect 14.0 %), had no significant effect on the difference
in the adherence outcome between the study groups at the
end of the study (rank-sum test; p = 0.97).
Figure 4 depicts the differences in the adherence out-
come by intervention component tested in the interven-
tion. Studies that included an EM-feedback type had a
mean improvement of 19.9 % (median 20.3 %), the
highest average among all intervention components. On
average, they were 7.7 % more effective than studies
testing intervention strategies that did not include such
feedback (rank-sum test; p = 0.02). Four studies used
rewards as part of the intervention strategies, providing a
mean improvement of adherence of 17.3 % and a median
of 22 % (the highest median among all intervention
components). On average, studies with rewards were
3.3 % more effective than studies without rewards (rank-
sum test; p = 0.44).
The occupation of the person who provided the inter-
vention had no significant effect on adherence measures
(rank-sum test; physician: effect = 1.0 % p = 0.99; nurse:
effect = 1.3 % p = 0.93; psychologist: effect = 4.7 %
p = 0.72; pharmacist: effect = 5.4 % p = 0.58; support
partner: effect = -5.8 % p = 0.45).
Fig. 3 Improvement in adherence outcome (percentage points) by
study duration (linear regression model) (n = 86) *Loess: locally
weighted scatterplot smoothing
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3.3.2 Significant Factors that Affect Adherence Outcomes:
Results from the Multiple Regression Model
When all variables were analyzed in a multiple regression
model using a stepwise method, the variable indicator of
EM-feedback type (p \ 0.01) and cognitive-educational
(p = 0.02) were the intervention components that
remained significant in the final model. The model esti-
mated an 8.8 % increase in adherence when the
intervention included an electronically monitored adher-
ence feedback system and 5.0 % increase in adherence
when the intervention included a cognitive-educational
component.
Study duration was also a significant factor that affected
adherence measures (p \ 0.01). For each additional month
of follow-up, the effect on adherence decreased by 1.1 %.
The variable percent adherent patient indicator (equal to 1
when the percentage of adherent patients is used as out-
come variable, 0 otherwise) was significant in the model
(p \ 0.01), indicating that the percentage of adherent
patients was not interchangeable with other adherence
measures (correct dosing, taking adherence, timing adher-
ence). The inclusion of the indicator variable in the model
then served a correction when this percentage of adherent
patients was used as an adherence measure.
3.3.3 Effects of Adherence-Enhancing Interventions
on Adherence Outcomes: Results from the
Meta-Analysis
Forty-eight of the 87 studies were included in the meta-
analysis. The excluded studies did not report the variability
Table 4 Effect of potential confounding factors on adherence mea-
sures: results from univariate regression models
Effect on improvement of
adherence measure in %
P value
Study duration (in weeks) -0.2430 \0.01












Fig. 4 Difference in the combined adherence outcome (expressed as
percentages) between intervention and control group by adherence-
enhancing component. The point near the middle of the box is the
median. The lower and upper bounds of the box are the 25th and 75th
percentile of the distribution. The ends of the whiskers represent the
minimum and the maximum of the distribution after taking out the
outliers. A point is considered as an outlier if it is above the 75th
percentile of the distribution plus 1.5 of the interquartile range or if it
is below the 25th percentile of the distribution minus 1.5 of the
interquartile range. The reported p values are based on the Wilcoxon
rank sum test to evaluate if there is any significant difference in
adherence amelioration outcome between studies that included the
corresponding intervention component and studies that did not
include this type of intervention component. TRT simpl Interventions
based on treatment simplification, Cogn-Educ cognitive-educational
interventions, Behav-Counsel behavioral-counseling interventions,
Soc-Psych social-psycho-affective intervention, EM-feedback inter-
ventions based on electronic-monitoring adherence feedback, Tech
rem interventions based on a technical reminder use, Tech equip
interventions based on a technical equipment use, Rewards any kind
of rewards for adhering to medications. The number of studies that
reported a statistical comparison between the groups (p value) and the
proportion of them that were statistically significant at the 5 % level
are depicted on the right-hand side
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of the effect of the intervention, which is needed to perform
the meta-analysis.
The forest plot reported in Fig. 5 illustrates the percentage
point differences in the adherence outcome between inter-
vention and control groups from the individual studies as well
as the estimated overall percentage point difference on
adherence based on random effects model. The estimated
overall percentage point difference between intervention and
control groups of the 48 studies was 12.6 % (95 % CI
9.4–15.8) with a wide variability in percentage point differ-
ences and confidence intervals between studies.
When explanatory variables were introduced in the
mixed-effect model of the meta-analysis, the EM-feedback
(p \ 0.01) and cognitive-educational (p = 0.04) element
of the intervention had a significant effect on patient
adherence. The model estimated an 8.7 % increase of the
adherence measure when the intervention included an
electronically monitored adherence feedback system and
5.6 % increase of adherence measure when the intervention
included an cognitive-educational component. Variable
study duration was also significant in this model (1.2 %
decrease for each month longer, p \ 0.01). The variable
percent adherence indicator was borderline significant in
this model (p = 0.09).
The combined adherence outcome in studies that tested
the EM-feedback type as part of the intervention showed an
overall percentage point difference of 19.8 % (95 % CI
10.7–28.9). The overall percentage point difference was
10.3 % (95 % CI 7.5–13.1) for the studies that did not test
the EM-feedback type as part of the intervention. The
improvement in adherence was 16.1 % (95 % CI
10.7–21.6 %) in studies testing cognitive-educational
components versus 10.1 % (95 % CI 6.6–13.6 %) in
studies that did not include this type of intervention.
3.4 Risk of Bias in Individual Studies
Out of 87 studies, 12 studies (13.8 %) were considered of
lower quality and prone to bias (1 had a score of -1 and 11
had a score of 0). Multiple regression analysis based on
high quality studies only confirmed that EM-feedback
(p \ 0.01) and the cognitive-educational (p = 0.01) ele-
ment of the intervention had a significant effect on patient
adherence. The model estimated a 7.7 % increase in the
adherence measure when the intervention included an
electronically monitored adherence feedback system and
5.9 % increase in the adherence measure when the inter-
vention included a cognitive-educational component. The
variable study duration (1.0 % decrease for each month
longer, p \ 0.01) and the variable percent adherence
indicator were significant in this model as well (p \ 0.01).
Fig. 5 Percentage point
differences in adherence
outcomes (ordered by year
of publication)
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3.5 Risk of Bias Across Studies
The Q statistic suggested considerable heterogeneity
among the true effects (p \ 0.01). The percentage of total
variability due to heterogeneity (I2) based on this model
was estimated as 99.9 %, showing that the studies were
heterogeneous.
By using the standardized mean difference in the meta-
analysis, the percentage of total variability due to hetero-
geneity (I2) based on this model was reduced slightly to
97.3 %. When explanatory variables were introduced in the
mixed-effect model of the meta-analysis, the Q statistic
remained significant (p \ 0.01), suggesting considerable
heterogeneity among the true effects.
The funnel plot (Fig. 6) showed possible publication
bias in studies with high variability of the intervention
effect. The regression test for funnel plot asymmetry [62]
showed that the observed mean difference in the adherence
outcome between the intervention and control group was
related to the standard error of the difference in the
adherence outcome (p \ 0.01). Studies with large inter-
vention effects gave low p values despite their high stan-
dard errors, and studies with p \ 0.05 were more likely to
be published.
4 Discussion
4.1 Summary of Evidence
In this systematic literature review, we identified 79 RCTs
reporting 87 pair-wise comparisons of interventions
intended to enhance patient adherence to prescribed
medications.
Patients randomized to an intervention group had, on
average, an adherence outcome that was 14.1 % higher
than in patients randomized to standard care. This effect
size is similar to the value reported in Peterson et al. [63]
who conducted a meta-analysis on adherence-enhancing
intervention trials and reported an overall effect size of
4–11 %, but no single strategy appeared to be best.
Relative to other intervention components, studies that
included an EM-feedback type had the largest mean
improvement in adherence measures. Studies using
rewards as part of the intervention had the largest median
improvement; however, probably due to its low sample
size, the effect is not significant. Intervention strategies that
included a focused discussion based on giving feedback to
the patient of his/her recent dosing history data (EM-
feedback) were 7.7 % more effective than intervention
strategies that did not include such feedback (p = 0.02).
The linear meta-regression analysis estimated an 8.8%
increase in adherence when the intervention included
feedback to the patients of their recent dosing history (EM-
feedback) (p \ 0.01). Our meta-analysis showed an aver-
age difference of 19.8 % (95 % CI 10.7–28.9 %) in the
combined adherence outcome between patients receiving
EM-feedback versus control group—almost double the
average difference among patients receiving an interven-
tion that did not include the EM-feedback versus control
group: 10.3 % (95 % CI 7.5–13.1 %).
This finding is consistent with the results of Kripalani
and colleagues [21] who reported that the most common
and effective forms of intervention were dosage simplifi-
cation and repeated assessment of medication adherence
with feedback. They used stringent inclusion criteria,
considering only studies in chronic medical conditions that
reported at least one measure of medication adherence and
one clinical outcome, and with at least 80 % follow-up of
patients during 6 months of treatment. The methods used to
measure adherence, however, varied widely in their
studies.
Another study recently highlighted that EM-feedback
can be a clinically useful tool when used in combination
with other adherence-promoting treatment strategies aimed
at enhancing medication adherence among chronically ill
youths [64].
Though EM-feedback can be considered as a behav-
ioral-counseling intervention, in terms of influencing
patients’ behavior by giving feedback on their recent drug
dosing history, it was considered as a separate intervention
component in our review. Given that our review focused on
studies that assessed medication adherence through elec-
tronic medication-event monitoring, we sought to investi-
gate how many studies utilized feedback on the patient’sFig. 6 Funnel plot to assess any publication bias across studies
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recent drug dosing history data in their intervention groups.
Twenty-two intervention groups (25.3 %) actually included
EM-feedback in their adherence-enhancing intervention.
Measurement-Guided Medication Management (MGMM)
of adherence may be an approach to enhance adherence to
medications in which reliable, detailed, recent, electroni-
cally compiled drug dosing history data are provided as
feedback to the patient on his/her adherence to prescribed
medications. It sets the stage for focused dialogue between
the healthcare providers and their patients, reinforcing
behavioral, social, and cognitive interventions.
Cognitive-educational interventions, designed to edu-
cate and motivate patients by instructional means, were
also significant intervention strategies in our final model.
The linear meta-regression analysis estimated a 5.0 %
increase in adherence when the intervention included a
cognitive-educational component (p = 0.02).
Non-adherence to medication is recognized as a multi-
factorial and complex problem. Most studies included in
our review assessed successfully complex interventions but
did not assess the separate effects of the components,
begging the question of whether all elements were
required.
Kripalani’s research group found in 2007 [21] that
complex programs which utilized multiple interventions
delivered over a longer period of time appeared more likely
to achieve better outcomes. It is likely that these more
complex interventions were effective because they address
a greater number of the potential barriers impacting a
patient’s ability to adhere to therapy and provide rein-
forcement over time.
In a review, Haynes et al. [9] reported that several
simple interventions appeared to improve adherence with
short-term regimens, but interventions to improve medi-
cation use for chronic conditions appeared less effective
overall and were often multifaceted, making it more diffi-
cult to synthesize published evaluation. This finding begs
the question of whether multiple components are necessary
or whether less complex interventions may be just as
effective.
Since the frequency or dose of the different intervention
components was not always clearly described in the studies
or sometimes somewhat confusing because of the multi-
plicity of the components tested, we could not draw any
conclusions on which intervention dose suits each com-
ponent best.
Our review highlights, nevertheless, that several inter-
ventions were effective in improving adherence to medi-
cations. Few of them, however, were able to demonstrate
an impact on clinical outcomes. While data on clinical
outcomes were reported in 57 studies, only 8 studies
(14.0 %) [35, 44, 52, 57–61] reported a significant differ-
ence in the effect of adherence-enhancing interventions on
clinical outcomes. Of note is that most studies were not
powered to show a difference in clinical outcomes, nor did
they control for other potential influences on the clinical
outcomes. There may also be a reporting bias; studies with
significant adherence outcomes but not significant clinical
outcomes may have not reported the non-significant clini-
cal outcomes. Kripalani and colleagues [21] drew the same
conclusion, having identified only a few studies demon-
strating an impact on clinical outcomes, despite including
only studies in which at least one measure of clinical
outcome was reported.
The duration of the study follow-up showed a significant
effect on the improvement in the combined adherence
outcome, suggesting that the intervention effects on
adherence tended to diminish over time. This evident
diminution in improvement has an important clinical
implication: it may not be realistic to expect a single epi-
sode of adherence-enhancing intervention to have long-
lasting effects. In two studies [38, 39], the intervention was
delivered on one occasion, with a statistically significant
effect on adherence outcomes, but the short follow-up
period did not allow for an estimation of the intervention’s
waning effect over time. Interventions may have to be
provided in a sustained fashion as an integral part of the
treatment plan in order to achieve and maintain adherence.
The RCTs included in this review often lacked a
detailed description of the control groups. Standard care
provided to control participants in intervention trials may
also contain effective behavior change techniques. De
Bruin et al. [65] performed a meta-analysis on the impact
of standard care on effects of adherence interventions in
HIV patients. The control groups of their review—report-
edly receiving ‘‘usual care’’—were actually exposed to
widely varying forms of effective adherence care. As the
capacity of standard care increased, fewer behavioral
problems remained, making it less likely that the inter-
vention will be effective. These findings suggest that
intervention effects will be systematically reduced in set-
tings with higher levels of standard care.
Estimation of adherence to medication may differ
according to the measure of adherence. Since we focused
on studies that used electronically compiled drug-dosing
histories, we could confidently exclude a potential bias
present in other systematic reviews that would have been
introduced by heterogeneous adherence measures. This
method of electronically compiled drug dosing histories is
considered to be the most reliable and the most detailed
approach for estimating adherence to medication in
ambulatory patients. Consequently, however, only a lim-
ited number of adherence-enhancing interventions may
have been included in this review.
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4.2 Limitations
This meta-analysis was limited by the heterogeneity of the
pooled data and the different medication adherence
definitions.
Furthermore, we included each randomized controlled trial
testing adherence-enhancing interventions. We did not apply
any quality appraisal during the paper’s selection process.
Given that the review was limited to EM monitoring of
adherence, we have probably included more studies of
MGMM than a review with broader inclusion criteria for
adherence measurement. A publication bias might exist
because only significant MGMM studies might be pub-
lished, and inferior comparators might be used (investiga-
tors are sold to the concept of MGMM, and are ‘‘EM
practitioners’’).
While studies on which electronic monitors are used to
automatically compile dosing history data provide the most
reliable estimate of adherence, some potential bias cannot be
excluded. For example, non-adherent patients may refuse to
participate in an adherence study, resulting in over-estimation
of medication adherence. On the other hand, some patients
who are adherent to the treatment may not use the electronic
monitors appropriately (e.g., pocket dosing, weekly orga-
nizers, etc.), resulting in potential under-estimation of
adherence. In general, those patients remain an exception and
are typically screened out by the investigators, but it cannot be
excluded that this phenomenon becomes less frequent among
patients receiving EM-feedback.
Among the RCTs reviewed, considerable variability was
evident with respect to study size, randomization method,
frequency of intervention repetition, potential bias, opera-
tional definition of adherence, identification of the inter-
vention types, study follow-up, definition of standard of
care, and inclusion criteria used. The lack of detailed
descriptions of control groups might have underestimated
the intervention effects. In contrast to our review,
McDonald et al. [10] conducted a descriptive review of the
included studies instead of a quantitative summarization
(i.e., meta-analysis) of findings across studies because of
the heterogeneity in the methodology of adherence-
enhancing intervention studies.
The majority of the papers did not clearly describe the
methods used. This problem, also highlighted by several
other authors [9, 66–68], led to discrepancies in data
extraction between the two reviewers that needed to be
resolved. A majority of studies reported significant differ-
ences in at least one adherence measure between the study
groups (19.7 % significant differences vs. 8.5 % non-sig-
nificant differences), but a potential publication bias across
the studies was identified through the funnel plot. We did
not search conference abstracts or other sources to quantify
this potential bias.
Finally, many of the studies (38.0 %) included in this
review involved patients with HIV. The high effect size
found in this review might be due to the assumption that
differences in the perceived severity of the various health
conditions in the studies may influence patients’ response
to adherence interventions.
4.3 Future Research
The limitations of this research support the need for future
studies to adhere to guidelines concerning the design,
conduct, analysis, and reporting of studies designed to
assess the effects of adherence-enhancing interventions
[67, 68].
Because there is a broad spectrum of reasons for non-
adherence, including unintentional as well as intentional,
any single intervention is not likely to be effective in
enhancing medication adherence. The most effective
approach might be based on patient stratification and per-
sonalized medicine, i.e., (1) identifying the patients with
sub-optimal adherence; (2) identifying the origins for non-
adherence, and (3) targeting those patients with a suitable
intervention. It might be worthwhile to identify those
patients most likely to respond to one form of intervention
versus another and estimate the impact of adherence-
enhancing interventions on clinical outcomes [9, 69].
Our review has shown that there is a large variability in
intervention studies, and we have consequently identified
several aspects that might help in improving the power of
future intervention trials. More specifically, interventional
trials should be adequately powered for a clinical endpoint,
use a sound adherence measure, and be statistically robust.
Researchers should be informed that the efficacy of
adherence-enhancing interventions wane over time, requir-
ing repeated administration and adequate patient follow-up to
ascertain not only long-term efficacy of interventions, but
also the frequency of repeated interventions.
Finally, settings of clinical trials are different from real
life, and researchers should place greater emphasis on
testing adherence-enhancing interventions in real life set-
tings, including evidence-based economic evaluations.
Furthermore, most intervention studies are designed to
change patient behavior, whereas healthcare system or
multilevel interventions are still in an early research stage.
It seems to be important to plan for suitable system-related
intervention studies.
5 Conclusions
To our knowledge, this is the first review to focus on
studies in which dosing histories were electronically
compiled at rates of data sampling high-enough to provide
558 J. Demonceau et al.
adequate definition of when doses were or were not taken.
Despite several limitations, this review supports the efficacy
of EM-feedback and cognitive-educational interventions.
Future research on adherence-enhancing interventions
should address the multifaceted nature of non-adherence and
utilize better study methods.
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